2017
Pharmacogenomics of off‐target adverse drug reactions
Garon SL, Pavlos RK, White KD, Brown NJ, Stone CA, Phillips EJ. Pharmacogenomics of off‐target adverse drug reactions. British Journal Of Clinical Pharmacology 2017, 83: 1896-1911. PMID: 28345177, PMCID: PMC5555876, DOI: 10.1111/bcp.13294.Peer-Reviewed Original ResearchConceptsAdverse drug reactionsSevere cutaneous adverse reactionsTarget adverse drug reactionsDrug reactionsImmunological memoryTherapeutic effectHuman leukocyte antigen (HLA) associationsCutaneous adverse reactionsStrong human leukocyte antigen (HLA) associationDrug therapeutic effectsIM-ADRsMaculopapular exanthemaClinical featuresOptimal therapySignificant morbidityAdverse reactionsAntigen associationsPharmacological actionsTherapeutic targetDisease pathophysiologyClinical phenotypePreclinical testingGreater riskDrug metabolismPatient safety
2007
Plasminogen Activator Inhibitor-1 as a Predictor of Postoperative Atrial Fibrillation After Cardiopulmonary Bypass
Pretorius M, Donahue BS, Yu C, Greelish JP, Roden DM, Brown NJ. Plasminogen Activator Inhibitor-1 as a Predictor of Postoperative Atrial Fibrillation After Cardiopulmonary Bypass. Circulation 2007, 116: i-1-i-7. PMID: 17846288, DOI: 10.1161/circulationaha.106.677906.Peer-Reviewed Original ResearchConceptsPostoperative atrial fibrillationPAI-1 antigen concentrationsCardiopulmonary bypassAtrial fibrillationPlasminogen activator inhibitor-1Remote historyIndependent predictorsActivator inhibitor-1Antigen concentrationPAI-1Development of AFRisk of AFInhibitor-1Administration of protaminePreoperative PAI-1Elective cardiac surgeryTime of surgeryPAI-1 concentrationsBlood of patientsHospital stayValve surgeryAdult patientsYounger patientsCardiac surgerySignificant morbidity